APLIKASI SEL iPSC SEBAGAI KANDIDAT TERAPI ADJUVAN REMODELING JANTUNG PASKA INFARK MIOKARD AKUT

Wira Winardi

Abstract


Abstrak:Penyakit jantung koroner telah diketahui sebagai salah satu masalah utama dalam pelayanan kesehatan di berbagai belahan dunia. Perkembangan terkini pengobatan Infark Miokard Akut (IMA) belum mampu menurunkan insidensi, angka rawat inap, serta angka kematian. Efek yang paling merugikan paska kejadian infark miokard akut adalah  remodeling jantung. Telah banyak penelitian yang menunjukkan potensi terapi sel punca untuk memperbaiki kerusakan jaringan jantung paska IMA. induced pluripotent stem cell (iPSC) adalah salah satu kandidat potensial sumber sel punca untuk terapi gagal jantung paska IMA. 

Abstract : Coronary Heart Disease is known as one of  major global health care problem. Recent advance of myocardial infarct therapy still not able to reduce incidence, hospitalization, and mortality. One of notable event following myocardial infarct is heart remodeling. Numerous of study showed stem cell potential to repair heart tissue after acute myocardial infarction. Induced pluripotent stem cell (iPSC) is one of potential candidate of stem cell resource for heart failure therapy post myocardial infarction.

 

 


Keywords


Infark Miokard Akut, remodeling jantung, induced pluripotent stem cell acute myocardial infarction, cardiac remodeling, induced pluripotent stem cells

Full Text:

PDF

References


Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. Journal of the American College of Cardiology. 2008;52(6):428-34.

Taylor DO, Edwards LB, Boucek MM, Trulock EP, Aurora P, Christie J, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2007;26(8):769-81.

Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. Journal of the American College of Cardiology. 2000;35(3):569-82.

Gherghiceanu M, Barad L, Novak A, Reiter I, Itskovitz-Eldor J, Binah O, et al. Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure. Journal of cellular and molecular medicine. 2011;15(11):2539-51.

Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(1):93-8.

Vidarsson H, Hyllner J, Sartipy P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem cell reviews. 2010;6(1):108-20.

Li N, Wang C, Jia L, Du J. Heart regeneration, stem cells, and cytokines. Regenerative medicine research. 2014;2(1):6.

Dixit P, Katare R. Challenges in identifying the best source of stem cells for cardiac regeneration therapy. Stem cell research & therapy. 2015;6:26.

Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation. 2003;108(17):2070-3.

Christoforou N, Gearhart JD. Stem cells and their potential in cell-based cardiac therapies. Progress in cardiovascular diseases. 2007;49(6):396-413.

Tongers J, Losordo DW, Landmesser U. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. European heart journal. 2011;32(10):1197-206.

Zaehres H, Scholer HR. Induction of pluripotency: from mouse to human. Cell. 2007;131(5):834-5.

Oh Y, Wei H, Ma D, Sun X, Liew R. Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine. Heart. 2012;98(6):443-9.

Seki T, Yuasa S, Kusumoto D, Kunitomi A, Saito Y, Tohyama S, et al. Generation and characterization of functional cardiomyocytes derived from human T cell-derived induced pluripotent stem cells. PloS one. 2014;9(1):e85645.

Raab S, Klingenstein M, Liebau S, Linta L. A Comparative View on Human Somatic Cell Sources for iPSC Generation. Stem cells international. 2014;2014:768391.

Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation research. 2009;104(4):e30-41.

Rojas SV, Martens A, Zweigerdt R, Baraki H, Rathert C, Schecker N, et al. Transplantation Effectiveness of Induced Pluripotent Stem Cells Is Improved by a Fibrinogen Biomatrix in an Experimental Model of Ischemic Heart Failure. Tissue engineering Part A. 2015;21(13-14):1991-2000.

Yamada S, Nelson TJ, Kane GC, Martinez-Fernandez A, Crespo-Diaz RJ, Ikeda Y, et al. Induced pluripotent stem cell intervention rescues ventricular wall motion disparity, achieving biological cardiac resynchronization post-infarction. The Journal of physiology. 2013;591(Pt 17):4335-49.

Medvedev SP, Shevchenko AI, Zakian SM. Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine. Acta naturae. 2010;2(2):18-28.


Refbacks

  • There are currently no refbacks.



Creative Commons LicenseISSN: 1411-3848E-ISSN: 2579-6372
Copyright© 1987-2017 | ISSN: 1412-1026 | EISSN: 2550-0112 
Jurnal Kedokteran Syiah Kuala is licensed under a Creative Commons Attribution 4.0 International License.

 

Published by:
Fakultas Kedokteran, Universitas Syiah Kuala
 
Jl. Tgk. Tanoh Abee, Kopelma Darussalam,
Banda Aceh, 23111, Indonesia.
Phone: +626517551843 
Email: jks@unsyiah.ac.id


Online Submissions & Guidelines | Editorial Policies | Contact | Statistics | Indexing | Citations